China
Medical device market intelligence for China. Regulatory changes, competitor moves, and procurement trends.
Country table last refreshed: Aug 9, 2026 (may lag). 7-day count above is live-recomputed (table had 341).
Last 7 days
China’s NMPA Approves Adjuvant T-DXd for HER2+ Early Breast Cancer With Residual Invasive Disease - OncLive
Harbour BioMed Receives China NMPA Approval Of Batoclimab Injection (Subcutaneous Injection) For The Treatment Of Generalized Myasthenia Gravis - www.marketscreener.com
HanAll Biopharma wins China approval for myasthenia gravis drug batoclimab - CHOSUNBIZ - Chosunbiz
Harbour BioMed's batoclimab wins China gMG approval amid HanAll licensing dispute - AllSci
Harbour BioMed Receives China NMPA Approval of Batoclimab Injection (Subcutaneous Injection) for the Treatment of Generalized Myasthenia Gravis - Newport Daily Express